Downregulation of stathmin 1 in human gallbladder carcinoma inhibits tumor growth in vitro and in vivo.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

RNA Interference*; Cell Proliferation/*genetics ; Gallbladder Neoplasms/*genetics ; Stathmin/*genetics ; Xenograft Model Antitumor Assays/*methods; Animals ; Cell Cycle/genetics ; Cell Line, Tumor ; Cell Movement/genetics ; Down-Regulation ; Female ; Gallbladder Neoplasms/metabolism ; Gallbladder Neoplasms/therapy ; Humans ; Immunohistochemistry ; Mice, Inbred BALB C ; RNAi Therapeutics/methods ; Stathmin/biosynthesis ; Tumor Burden/genetics

Gallbladder carcinoma (GBC) is a highly lethal malignancy of the gastrointestinal tract. Despite extensive research, the underlying molecular mechanism of GBC remains largely unclear. Stathmin 1 (STMN1) is an important cytosolic protein associated with microtubule stability that was reported to be involved in tumorigenesis. Up to our knowledge, its role in gallbladder carcinoma has not been analyzed. In this study, we found that STMN1 was significantly highly expressed in GBC by immunohistochemistry (IHC). Further research demonstrated that silencing of STMN1 inhibited cell growth in vitro. Moreover, knockdown of STMN1 induced apoptosis and delayed G2/M phase transformation in GBC cells. Our data support a rationale for further studies that the silencing of STMN1 may regulate the activity of p38 MAPK kinase and p53/p21 signal pathway. Besides, xenografted gallbladder carcinoma cells growth were significantly impaired after STMN1 was silenced in vivo. These results suggested that STMN1 played an important role in cell proliferation and migration. This provided a potential clue for investigating the therapeutic target in GBC.

J Proteome Res. 2010 Oct 1;9(10):4897-905. (PMID: 20806969)
Hepatobiliary Surg Nutr. 2014 Oct;3(5):221-6. (PMID: 25392833)
Acta Biochim Biophys Sin (Shanghai). 2014 Dec;46(12):1034-40. (PMID: 25348735)
J Biol Chem. 1988 Sep 15;263(26):12813-5. (PMID: 3417633)
Oncotarget. 2015 Oct 6;6(30):29573-84. (PMID: 26356819)
J Am Coll Surg. 2011 Jan;212(1):50-61. (PMID: 21075015)
Pathol Oncol Res. 2015 Jul;21(3):509-25. (PMID: 25618479)
J Surg Oncol. 2011 Jun 1;103(7):704-15. (PMID: 21360534)
Expert Rev Anticancer Ther. 2008 Sep;8(9):1461-70. (PMID: 18759697)
Oncol Res. 2016;23 (1-2):35-41. (PMID: 26802649)
J Oncol. 2015;2015:967472. (PMID: 26421012)
Cancer Biol Ther. 2010 May 1;9(9):699-709. (PMID: 20200495)
Langenbecks Arch Surg. 2012 Aug;397(6):899-907. (PMID: 22454256)
Cytoskeleton (Hoboken). 2012 May;69(5):278-89. (PMID: 22407961)
Prostate. 1995 Aug;27(2):102-9. (PMID: 7638082)
Br J Cancer. 2000 Jan;82(1):142-50. (PMID: 10638981)
Int J Cancer. 1997 Nov 27;73(5):678-83. (PMID: 9398045)
World J Gastroenterol. 2016 Jan 28;22(4):1335-47. (PMID: 26819503)
Oncogene. 2007 Feb 15;26(7):1003-12. (PMID: 16909102)
Updates Surg. 2015 Dec;67(4):339-51. (PMID: 26563387)
Int J Cancer. 2002 Jan 1;97(1):121-8. (PMID: 11774253)
Oncogene. 2001 Apr 5;20(15):1803-15. (PMID: 11313928)
Expert Opin Ther Targets. 2011 Nov;15(11):1249-66. (PMID: 21978024)
J Transl Med. 2013 Sep 16;11:212. (PMID: 24040910)

0 (STMN1 protein, human)
0 (Stathmin)

Date Created: 20160629 Date Completed: 20180515 Latest Revision: 20220330

20240628

PMC4923895

10.1038/srep28833

27349455